The company’s corporate headquarters are located at 501 Boylston Street, Suite 6102, Boston MA, 02116.
Gelesis is incorporated in the state of Delaware.
Gelesis common stock began trading on the New York Stock Exchange on January 14, 2022, under the symbol “GLS.” The CUSIP number is 36850R 204 and the ISIN number is US36850R2040.
Gelesis does not currently have a direct stock purchase plan. Please contact your personal brokerage firm to purchase shares of Gelesis common stock.
Gelesis does not currently or anticipate paying any dividends in the near future.
The company’s agent is Continental Transfer Agent.
All such inquiries should be directed to the transfer agent above. Gelesis is not able to process any stock transfers unless through its transfer agent.
Gelesis’ independent registered public accounting firm is KPMG LLP.
Annual reports and proxy statements, in addition to all other SEC filings, can be found within the SEC Filings section of the website, or at www.sec.gov.
Please refer to the News section for the most recent business updates on Gelesis.
Please refer to the News and the Events & Presentations section.
The company’s fiscal year ends with the calendar year on December 31.
Please refer to the Governance section.
Please refer to the Investor Email Alerts section; you may sign up to receive alerts there.
Please contact IR@Gelesis.com for more information.